Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II intra-arterial cetuximab sarotalocan sodium photoimmunotherapy plus pembrolizumab for recurrent or metastatic head and neck cancer
jRCT2031260488Phase 2Recruiting
- Sponsor
- Nippon Medical School Hospital
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab sarotalocan sodium and pembrolizumab in head and neck cancer (HNC), sponsored by Nippon Medical School Hospital. Primary endpoints: Dose-limiting toxicity incidence and Objective response rate. Started Sep 2026; status: recruiting.
02
Drugs
cetuximab sarotalocan sodiumpembrolizumab
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on jRCT2031260488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260488.